切换至 "中华医学电子期刊资源库"

中华肾病研究电子杂志 ›› 2019, Vol. 08 ›› Issue (04) : 159 -162. doi: 10.3877/cma.j.issn.2095-3216.2019.04.004

所属专题: 文献

论著

乙型肝炎病毒相关膜性肾病患者抗血清磷脂酶A2受体-IgG特点及其相关因素的临床研究
戴沛霖1, 杨悦2, 涂天琪3, 李文歌3,()   
  1. 1. 100083 北京大学医学部中日友好临床医学院;100029 国家卫健委中日友好医院 肾病科
    2. 100029 国家卫健委中日友好医院 肾病科
  • 收稿日期:2018-12-19 出版日期:2019-08-28
  • 通信作者: 李文歌

Characteristics of serum anti-phospholipase A2 receptor-IgG and its related factors in patients with hepatitis B virus-associated membranous nephropathy

Peilin Dai1, Yue Yang2, Tianqi Tu3, Wenge Li3,()   

  1. 1. China-Japan Friendship Clinical Medical College of Peking University, Beijing 100083, China; Department of Nephropathy, China-Japan Friendship Hospital of National Health Commission, Beijing 100029, China
    2. Department of Nephropathy, China-Japan Friendship Hospital of National Health Commission, Beijing 100029; China
    3. China-Japan Friendship Clinical Medical College of Peking University, Beijing 100083, China; Department of Nephropathy, China-Japan Friendship Hospital of National Health Commission, Beijing 100029; China
  • Received:2018-12-19 Published:2019-08-28
  • Corresponding author: Wenge Li
  • About author:
    Corresponding author: Li Wenge, Email:
引用本文:

戴沛霖, 杨悦, 涂天琪, 李文歌. 乙型肝炎病毒相关膜性肾病患者抗血清磷脂酶A2受体-IgG特点及其相关因素的临床研究[J/OL]. 中华肾病研究电子杂志, 2019, 08(04): 159-162.

Peilin Dai, Yue Yang, Tianqi Tu, Wenge Li. Characteristics of serum anti-phospholipase A2 receptor-IgG and its related factors in patients with hepatitis B virus-associated membranous nephropathy[J/OL]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2019, 08(04): 159-162.

目的

研究乙型肝炎病毒相关膜性肾病(HBV-MN)患者血清抗磷脂酶A2受体(PLA2R)-IgG阳性率,分析与PLA2R-IgG滴度相关的因素。

方法

本研究纳入经肾穿刺活检确诊的HBV-MN患者108例,检测血清PLA2R-IgG滴度、肌酐、白蛋白和24 h尿蛋白定量等,计算肾小球滤过率,分别统计患者肾活检组织中PLA2R及免疫荧光IgG、C3、C1q及IgG亚型阳性率,分析年龄、性别、蛋白尿与血清中和肾活检组织中PLA2R-IgG检测结果的关系。

结果

108例HBV-MN患者中,血清PLA2R-IgG阳性率为37%,肾组织PLA2R阳性率54.6%,血清PLA2R-IgG的阳性率和滴度与年龄、性别无统计学相关性(P>0.05),与尿蛋白水平相关(χ2=9.159,P=0.010;χ2=11.327,P=0.004);尿蛋白>3.5 g/d组患者PLA2R-IgG阳性率显著高于尿蛋白<1g/d及1~3.5 g/d组(Z=2.863,P=0.012和Z=2.356,P=0.049)。

结论

HBV-MN患者中PLA2R-IgG阳性率较高,阳性率及滴度均与蛋白尿水平相关,尿蛋白越多,阳性率和滴度也随之升高。

Objective

To study the positive rate of serum anti-phospholipase A2 receptor (PLA2R)-IgG in patients with hepatitis B virus-associated membranous nephropathy (HBV-MN), and to analyze the factors related to anti-PLA2R-IgG titer.

Methods

In this study, 108 patients with HBV-MN diagnosed by renal biopsy were enrolled. The titers of serum PLA2R-IgG, serum creatinine, and serum albumin, as well as 24 h urine protein were measured. The glomerular filtration rate was calculated. The positive rates of PLA2R expression and the immunofluorescence of IgG, C3, and C1q besides IgG subtypes in the renal biopsy tissues were counted. And the relationships between age, gender, or proteinuria and anti-PLA2R-IgG detection results from serum and renal biopsies were analyzed.

Results

Among the 108 patients with HBV-MN, the positive rate of serum anti-PLA2R-IgG was 37%, and the positive rate of PLA2R in the renal tissues was 54.6%. The positive rate and titer of serum anti-PLA2R-IgG were not statistically correlated with age and gender (P>0.05), but were correlated with the urinary protein levels (χ2=9.159, P=0.010; χ2=11.327, P=0.004). patients with urinary protein>3.5 g/d have significantly higher positive rate than patients with urinary protein <1 g/d and 1-3.5 g/d group (Z=2.863, P=0.012 and Z=2.356, P=0.049).

Conclusion

The positive rate of anti-PLA2R-IgG was high in the HBV-MN patients, and its positive rate and titer were associated with the proteinuria level. The higher proteinuria level, the higher positive rate and titer of anti-PLA2R-IgG.

表1 入选患者临床特征和检测数据(n=108)
图1 HBV-MN肾小球及肾小管损伤情况(PASM染色,400×)
图2 HBV-MN患者肾组织切片免疫荧光染色(400×)
图3 HBV-MN患者蛋白尿与血清PLA2R-IgG
[1]
Beck LH, Jr.Bonegio RG, Lambeau G, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy [J]. N Engl J Med, 2009, 361(1): 11-21.
[2]
Geneva: World Health Organization. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection [EB/OL]. 2015:

URL    
[3]
Mast EE, Margolis HS, Fiore AE, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children, and adolescents [J]. MMWR Recomm Rep, 2005, 54(RR-16): 1-31.
[4]
Yang Y, Zhang Z, Zhuo L, et al. The spectrum of biopsy-proven glomerular disease in China: a systematic review [J]. Chin Med J (Engl), 2018, 131(6): 731-735.
[5]
Pourcine F, Dahan K, Mihout F, et al. Prognostic value of PLA2R autoimmunity detected by measurement of anti-PLA2R antibodies combined with detection of PLA2R antigen in membranous nephropathy: a single-centre study over 14 years [J]. PLoS One, 2017, 12(3): e0173201.
[6]
Xie Q, Li Y, Xue J, et al. Renal phospholipase A2 receptor in hepatitis B virus-associated membranous nephropathy [J]. Am J Nephrol, 2015, 41(4-5): 345-353.
[7]
Lin L, Wang WM, Pan XX, et al. Biomarkers to detect membranous nephropathy in Chinese patients [J]. Oncotarget, 2016, 7(42): 67868-67879.
[8]
Wang J, Cui Z, Lu J, et al. Circulating antibodies against thrombospondin type-I domain-containing 7A in Chinese patients with idiopathic membranous nephropathy [J]. Clin J Am Soc Nephrol, 2017, 12(10): 1642-1651.
[9]
Hofstra JM, Beck LH, Jr. Beck DM, et al. Anti-phospholipase A(2) receptor antibodies correlate with clinical status in idiopathic membranous nephropathy [J]. Clin J Am Soc Nephrol, 2011, 6(6): 1286-1291.
[10]
Hoxha E, Thiele I, Zahner G, et al. Phospholipase A2 receptor autoantibodies and clinical outcome in patients with primary membranous nephropathy [J]. J Am Soc Nephrol, 2014, 25(6): 1357-1366.
[1] 王亚红, 蔡胜, 葛志通, 杨筱, 李建初. 颅骨骨膜窦的超声表现一例[J/OL]. 中华医学超声杂志(电子版), 2024, 21(11): 1089-1091.
[2] 唐金侨, 叶宇佳, 王港, 赵彬, 马艳宁. 医学影像学检查方法在颞下颌关节紊乱病中临床应用研究进展[J/OL]. 中华口腔医学研究杂志(电子版), 2024, 18(06): 406-411.
[3] 赵林娟, 吕婕, 王文胜, 马德茂, 侯涛. 超声引导下染色剂标记切缘的梭柱型和圆柱型保乳区段切除术的效果研究[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 634-637.
[4] 屈翔宇, 张懿刚, 李浩令, 邱天, 谈燚. USP24及其共表达肿瘤代谢基因在肝细胞癌中的诊断和预后预测作用[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 659-662.
[5] 熊鹰, 林敬莱, 白奇, 郭剑明, 王烁. 肾癌自动化病理诊断:AI离临床还有多远?[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(06): 535-540.
[6] 中华医学会器官移植学分会. 肝移植术后缺血性胆道病变诊断与治疗中国实践指南[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 739-748.
[7] 郑大雯, 王健东. 胆囊癌辅助诊断研究进展[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 769-773.
[8] 袁雨涵, 杨盛力. 体液和组织蛋白质组学分析在肝癌早期分子诊断中的研究进展[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 883-888.
[9] 王秋生. 胆道良性疾病诊疗策略[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 779-782.
[10] 李浩, 陈棋帅, 费发珠, 张宁伟, 李元东, 王硕晨, 任宾. 慢性肝病肝纤维化无创诊断的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(09): 863-867.
[11] 谭瑞义. 小细胞骨肉瘤诊断及治疗研究现状与进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(08): 781-784.
[12] 王子阳, 王宏宾, 刘晓旌. 血清标志物对甲胎蛋白阴性肝细胞癌诊断的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 677-681.
[13] 陈慧, 邹祖鹏, 周田田, 张艺丹, 张海萍. 皮肤镜对头皮红斑性皮肤病辅助鉴别诊断的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 692-698.
[14] 胡云鹤, 周玉焯, 付瑞瑛, 于凡, 李爱东. CHS-DRG付费制度下GB1分组住院费用影响因素分析与管理策略探讨[J/OL]. 中华临床医师杂志(电子版), 2024, 18(06): 568-574.
[15] 奚培培, 周加军. 慢性肾脏病患者肌少症机制和诊治的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(05): 491-495.
阅读次数
全文


摘要